<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CSNK1D - Casein Kinase 1 Delta</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CSNK1D</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Casein Kinase 1 Delta</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>CK1δ, CKID, CKI-delta</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1453</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>604065</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000141552</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P48730</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>409 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>47 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (hypothalamus, SCN, cortex, hippocampus), liver, lung</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Brain Expression</td>
</tr>
<tr>
<td class="label">CK1δ</td>
<td>High</td>
</tr>
<tr>
<td class="label">CK1ε</td>
<td>High</td>
</tr>
<tr>
<td class="label">CK1α</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">CK1β</td>
<td>Neuronal</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CSNK1D - Casein Kinase 1 Delta</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CSNK1D</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Casein Kinase 1 Delta</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>CK1δ, CKID, CKI-delta</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1453</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>604065</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000141552</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P48730</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>409 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>47 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (hypothalamus, SCN, cortex, hippocampus), liver, lung</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Brain Expression</td>
</tr>
<tr>
<td class="label">CK1δ</td>
<td>High</td>
</tr>
<tr>
<td class="label">CK1ε</td>
<td>High</td>
</tr>
<tr>
<td class="label">CK1α</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">CK1β</td>
<td>Neuronal</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">20 edges</a></td>
</tr>
</table>
CSNK1D (Casein Kinase 1 Delta) is a serine/threonine protein kinase that plays critical roles in multiple cellular processes, including circadian rhythm regulation, Wnt signaling, DNA damage response, and protein trafficking. Located on chromosome 15q21.3, this gene encodes a protein that has garnered significant attention in neurodegenerative disease research due to its involvement in tau phosphorylation, alpha-synuclein processing, and circadian dysfunction—all key features of [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease)[@knappe2020].
Casein kinase 1 delta (CK1δ) is one of six members of the casein kinase 1 family (CK1α, CK1β, CK1γ, CK1δ, CK1ε, and CK1ζ), which are highly conserved serine/threonine kinases found in all eukaryotes. CK1δ and its close relative CK1ε are the most abundantly expressed isoforms in the brain and have been strongly linked to neurodegenerative processes through their ability to phosphorylate proteins central to disease pathogenesis[@marin2021].
The importance of CSNK1D in neurodegeneration extends beyond its enzymatic function. Mutations in CSNK1D cause familial advanced sleep phase syndrome (FASPS), demonstrating its critical role in circadian rhythm control. Given the well-established relationship between circadian disruption and neurodegenerative disease progression, CSNK1D represents a molecular nexus connecting circadian dysfunction to neurodegeneration[@shen2021].
CK1δ possesses the typical bilobed kinase structure seen in all protein kinases[@roberson2006]:
N-terminal lobe (residues 1-120): Contains five β-strands and a crucial α-helix (αC) that undergoes conformational changes during catalysis. This region contributes to ATP binding and positioning of the substrate.
C-terminal lobe (residues 150-350): Predominantly α-helical and provides the structural framework for peptide substrate binding. The active site is located in the cleft between the two lobes.
Activation segment (residues 170-190): Contains the activation loop whose phosphorylation state modulates kinase activity. Unlike many kinases, CK1δ does not require phosphorylation for basal activity but can be regulated by this mechanism.
CK1δ exhibits constitutive kinase activity, phosphorylating serine and threonine residues in various contexts. The consensus sequence for CK1δ phosphorylation is typically (S/T)-X-X-(S/T), where X can be any amino acid. However, CK1δ also phosphorylates sites that deviate from this consensus, particularly in protein substrates like tau and PER proteins[@siddiqui2012].
The catalytic efficiency (kcat/Km) of CK1δ varies considerably depending on the substrate, reflecting the importance of substrate recognition beyond the minimal consensus sequence. Docking interactions and structural features surrounding the phosphorylation site significantly influence CK1δ activity.
CK1δ activity is regulated through multiple mechanisms:
Within the central nervous system, CK1δ is widely expressed with particularly high levels in[@arevalo2010]:
Suprachiasmatic Nucleus (SCN): The master circadian clock in the hypothalamus shows very high CK1δ expression, where it plays essential roles in circadian rhythm generation. CK1δ phosphorylates PER1 and PER2 proteins, regulating their stability and nuclear accumulation.
Hypothalamus: Beyond the SCN, CK1δ is expressed throughout the hypothalamus, where it participates in various neuroendocrine functions.
Cortex: Cortical neurons express CK1δ, where it contributes to synaptic plasticity, protein trafficking, and disease-related processes.
Hippocampus: The hippocampus shows high CK1δ expression, particularly in pyramidal neurons. This region is critical for memory formation and is severely affected in [Alzheimer's Disease](/diseases/alzheimers-disease).
Cerebellum: CK1δ is expressed in Purkinje cells and other cerebellar neurons, where it participates in motor learning and coordination.
CK1δ exhibits both cytoplasmic and nuclear localization in neurons. In the cytoplasm, it associates with various organelles including the Golgi apparatus, endoplasmic reticulum, and synaptic vesicles. Nuclear CK1δ concentrates in the nucleoplasm and is particularly associated with the nuclear envelope. This subcellular distribution allows CK1δ to participate in diverse cellular processes.
CK1δ (along with CK1ε) is a key component of the core circadian clock machinery[@chen2020]:
PER phosphorylation: CK1δ phosphorylates PER1, PER2, and PER3 proteins, promoting their recognition by the F-box protein FBXL3 and subsequent degradation by the proteasome. This phosphorylation is critical for circadian period determination.
Clock gene regulation: By controlling PER protein stability, CK1δ directly influences the expression of CLOCK-BMAL1 target genes, including other clock components and output genes.
Casein kinase mutations and circadian phenotypes: The FASPS-causing mutations in CSNK1D (T44A) and CSNK1E (CSNK1E) reduce PER2 phosphorylation, leading to faster degradation and advanced circadian phase.
The connection between CK1δ and circadian rhythm is particularly relevant to neurodegeneration, as circadian dysfunction is increasingly recognized as both a symptom and potential contributor to neurodegenerative diseases.
CK1δ is one of the key kinases that phosphorylates [tau](/proteins/tau) protein at multiple sites relevant to [Alzheimer's Disease](/diseases/alzheimers-disease) pathogenesis[@liu2020]:
Tau pathological sites: CK1δ phosphorylates tau at sites including Thr181, Ser199, Ser202, Thr205, Ser396, and Ser404. Many of these sites are hyperphosphorylated in neurofibrillary tangles.
Tau aggregation: Phosphorylation by CK1δ promotes tau aggregation into paired helical filaments. The phosphorylation status of tau influences its ability to form pathological aggregates.
GSK-3β collaboration: CK1δ often works in concert with [GSK-3β](/proteins/gsk3-beta-protein), another major tau kinase. CK1δ can prime tau for subsequent GSK-3β phosphorylation, creating a hierarchical phosphorylation cascade.
CK1δ participates in the [Wnt signaling pathway](/mechanisms/wnt-signaling) through phosphorylation of key components[@huang2019]:
Dishevelled phosphorylation: CK1δ phosphorylates Dishevelled (Dvl), a key mediator of canonical and non-canonical Wnt signaling. This phosphorylation regulates Dvl function and downstream signaling outcomes.
β-catenin regulation: Through effects on Dvl and potentially direct phosphorylation of [β-catenin](/proteins/beta-catenin-protein), CK1δ influences β-catenin stability and transcriptional activity.
Relevance to neurodegeneration: Wnt signaling is important for neuronal development, synaptic plasticity, and neuroprotection. Dysregulation of Wnt signaling has been implicated in AD pathogenesis.
CK1δ contributes to the DNA damage response through phosphorylation of key repair proteins[@wu2020]:
p53 phosphorylation: CK1δ can phosphorylate p53 at Ser15, contributing to p53 activation following DNA damage. This may influence neuronal survival following genotoxic stress.
Repair protein regulation: CK1δ phosphorylates various DNA repair proteins, modulating their activity and recruitment to damage sites.
Relevance to neurodegeneration: Neuronal DNA damage accumulates with age and in neurodegenerative diseases. CK1δ's role in DNA damage response may influence neuronal viability under these conditions.
In [Parkinson's Disease](/diseases/parkinsons-disease), CK1δ may phosphorylate [alpha-synuclein](/proteins/alpha-synuclein) at relevant sites[@mousavi2020]:
Ser129 phosphorylation: While PLK3 and GRK5 are considered the major kinases for Ser129 phosphorylation, CK1δ may contribute under certain conditions.
Aggregation regulation: Phosphorylation of alpha-synuclein influences its aggregation propensity, with CK1δ-mediated phosphorylation potentially affecting pathological processes.
CK1δ is strongly implicated in [Alzheimer's Disease](/diseases/alzheimers-disease) pathogenesis[@knappe2020]:
Tau hyperphosphorylation: CK1δ-mediated tau phosphorylation contributes to the formation of neurofibrillary tangles. CK1δ activity is increased in AD brain, potentially driving pathological tau modification.
Amyloid-β effects: [Amyloid-beta](/proteins/amyloid-beta) accumulation can stimulate CK1δ activity, creating a positive feedback loop between amyloid and tau pathology.
Circadian dysfunction: CK1δ dysregulation contributes to the circadian disturbances commonly observed in AD patients, including sleep fragmentation and sundowning.
Synaptic dysfunction: CK1δ phosphorylates synaptic proteins and may contribute to synaptic loss through effects on synaptic plasticity and protein trafficking.
CK1δ involvement in [Parkinson's Disease](/diseases/parkinsons-disease) includes[@zhang2019]:
Alpha-synuclein processing: CK1δ may phosphorylate alpha-synuclein and influence its aggregation into Lewy bodies.
Circadian disruption: Like AD, PD is associated with circadian dysfunction. CK1δ alterations may contribute to sleep disturbances in PD.
Dopaminergic neuron vulnerability: CK1δ activity affects mitochondrial function and may influence the selective vulnerability of dopaminergic neurons.
LRRK2 interaction: CK1δ may interact with [LRRK2](/genes/lrrk2) pathogenic variants, which are a major cause of familial PD.
In [Huntington's Disease](/diseases/huntington-disease), CK1δ plays important roles[@zhou2020]:
Mutant huntingtin phosphorylation: CK1δ phosphorylates mutant [huntingtin](/proteins/huntingtin) protein, influencing its aggregation and toxicity.
Transcriptional dysregulation: Through effects on transcription factors, CK1δ contributes to the transcriptional dysfunction characteristic of HD.
Circadian abnormalities: HD patients show significant circadian disruption, potentially involving CK1δ dysregulation.
CK1δ plays important roles in synaptic plasticity and memory formation[@xu2021]:
CK1δ contributes to LTP through phosphorylation of:
CK1δ activity is required for:
Alterations in CK1δ-mediated synaptic signaling contribute to:
Given the clear involvement of CK1δ in neurodegenerative disease pathogenesis, CK1δ inhibitors have been actively investigated[@martinez2021]:
PF-670462: This selective CK1δ/ε inhibitor has been studied for circadian rhythm disorders and shows neuroprotective properties in preclinical models.
IC261: A CK1δ/ε inhibitor that has demonstrated effects on tau phosphorylation and neuroprotection in model systems.
DRF053: A dual CK1δ/CK1ε inhibitor with potential therapeutic applications.
Challenges: Achieving brain penetration and selectivity while minimizing peripheral side effects remains challenging. The widespread roles of CK1δ in normal physiology also raise concerns about potential toxicity.
Given CK1δ's central role in circadian regulation[@tanaka2021]:
Targeting circadian dysfunction: Improving circadian function through light therapy, melatonin, or other interventions may provide benefits in neurodegenerative diseases.
Chronopharmacology: Timing of therapeutic interventions based on circadian rhythms may improve efficacy.
Given the multiple pathways involved:
Kinase inhibitor combinations: Combining CK1δ inhibitors with inhibitors of other tau kinases (e.g., GSK-3β) may provide more comprehensive effects.
Multi-target approaches: Developing compounds that modulate both CK1δ and other relevant targets may be beneficial.
Current research focuses on[@kelley2021]:
Brain-penetrant inhibitors: Developing CK1δ inhibitors with improved CNS penetration.
Selective targeting: Identifying more selective inhibitors to minimize off-target effects.
Biomarker development: Identifying biomarkers to monitor target engagement and treatment response.
The connection between CSNK1D, circadian regulation, and neurodegeneration deserves special attention:
Neurodegeneration affects circadian function: Damage to brain regions controlling circadian rhythms, including the SCN, leads to circadian dysfunction in neurodegenerative diseases.
Circadian dysfunction contributes to neurodegeneration: Disrupted circadian rhythms can exacerbate oxidative stress, inflammation, and other pathological processes.
SCN protection: Strategies that preserve SCN function may help maintain circadian rhythms in neurodegenerative diseases.
Circadian enhancement: Interventions that strengthen circadian rhythms may slow neurodegenerative progression.
CK1δ plays important roles in cellular stress responses that are relevant to neurodegeneration:
Oxidative Stress: CK1δ activity is modulated by oxidative stress, and CK1δ phosphorylates stress response proteins including Nrf2 transcription factor.
Heat Shock Response: CK1δ phosphorylates heat shock factor (HSF1), influencing the heat shock protein response.
ER Stress: CK1δ participates in the unfolded protein response through phosphorylation of PERK and other UPR components.
CK1δ influences mitochondrial function through multiple mechanisms:
Mitochondrial Dynamics: CK1δ phosphorylates proteins involved in mitochondrial fission and fusion, including Drp1.
Mitophagy: CK1δ regulates mitophagy through effects on PINK1 and Parkin, relevant to Parkinson's disease.
Metabolic Regulation: CK1δ influences glycolysis and oxidative phosphorylation through metabolic enzyme phosphorylation.
CK1δ modulates synaptic function through phosphorylation of synaptic proteins:
Presynaptic Function: CK1δ regulates synaptic vesicle release and recycling.
Postsynaptic Function: CK1δ phosphorylates AMPA and NMDA receptor subunits, affecting synaptic plasticity.
Homeostatic Plasticity: CK1δ participates in homeostatic synaptic scaling responses.
The casein kinase 1 family has multiple isoforms with distinct and overlapping functions:
The high expression of CK1δ in brain and its specific substrate preferences make it a key therapeutic target.
Progress in developing CK1δ-targeted therapeutics:
Selectivity Challenges: Achieving selectivity for CK1δ over other isoforms is difficult due to high similarity in the kinase domain.
Brain Penetration: Many CK1 inhibitors have poor blood-brain barrier penetration.
Clinical Trials: Several CK1 inhibitors have reached clinical trials for various indications, providing safety and efficacy data.
Novel Approaches: Allosteric inhibitors and substrate-targeting compounds offer alternative strategies.
The role of CK1δ in circadian rhythm has therapeutic implications:
Light Entrainment: CK1δ activity is modulated by light, the primary zeitgeber for circadian entrainment.
Phase Response Curve: CK1δ inhibition shifts the phase response curve to light.
Therapeutic Timing: Circadian-based timing of therapeutic interventions (chronotherapy) may improve outcomes.
Monitoring CK1δ activity in disease:
Phospho-biomarkers: Phosphorylation status of CK1δ substrates as surrogate markers.
Activity Assays: Functional assays measuring CK1δ activity in patient samples.
Imaging: PET tracers targeting CK1δ-expressing cells.
Key questions driving future research:
CK1δ intersects with multiple disease pathways:
Tau Pathology: CK1δ is a major tau kinase; its activity drives NFT formation.
Synaptic Dysfunction: CK1δ phosphorylates synaptic proteins, affecting plasticity.
Circadian Disruption: CK1δ dysregulation contributes to sleep disturbances.
Protein Aggregation: CK1δ affects aggregation of multiple proteins.
Translating CK1δ research into clinical applications:
Biomarker Development: CK1δ activity as a disease biomarker.
Therapeutic Targeting: CK1δ inhibitors in clinical trials.
Chronotherapy: Timing interventions to circadian rhythms.
Combination Approaches: Multi-target kinase inhibition strategies.
CK1δ function varies across cell types:
Neurons: High CK1δ expression; critical for synaptic function.
Astrocytes: CK1δ in astrocytic signaling and function.
Microglia: CK1δ in microglial inflammatory responses.
Oligodendrocytes: CK1δ in myelination and oligodendrocyte function.
CK1δ interacts with other kinases:
GSK-3β: Sequential phosphorylation of tau substrates.
CDK5: Collaboration in tau phosphorylation.
PKA: Cross-talk in circadian regulation.
CaMKII: Synaptic plasticity interactions.
CK1δ is a serine/threonine kinase with critical roles in circadian rhythm regulation, tau phosphorylation, Wnt signaling, and DNA damage response. Its involvement in Alzheimer's disease, Parkinson's disease, and Huntington's disease makes it an important therapeutic target. The development of brain-penetrant, selective CK1δ inhibitors remains a key goal, alongside circadian-based therapeutic approaches. As research progresses, CK1δ-targeted interventions may provide disease-modifying benefits for neurodegenerative disorders.